EAM Investors’s Aldeyra Therapeutics ALDX Stock Holding History

EAM Investors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-92,522	Closed	-$499K	–	256
2024 Q3	$499K	Buy	+92,522	New	+$440K	0.07%	231
2023 Q2	–	Sell	-211,388	Closed	-$2.1M	–	260
2023 Q1	$2.1M	Buy	211,388 +13,160	+7%	+$93K	0.41%	94
2022 Q4	$1.38M	Sell	198,228 -35,410	-15%	-$202K	0.29%	160
2022 Q3	$1.25M	Buy	+233,638	New	+$1.4M	0.27%	162
2021 Q3	–	Sell	-328,539	Closed	-$3.72M	–	281
2021 Q2	$3.72M	Buy	328,539 +225,348	+218%	+$2.71M	0.57%	33
2021 Q1	$1.23M	Buy	+103,191	New	+$1.19M	0.18%	269
2019 Q1	–	Sell	-310,024	Closed	-$2.57M	–	251
2018 Q4	$2.57M	Sell	310,024 -2,068	-0.7%	-$21.2K	0.7%	27
2018 Q3	$4.31M	Buy	+312,092	New	+$2.53M	0.64%	25

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

EAM Investors's ALDX Position: Q4 2024 in Review

EAM Investors sold out of Aldeyra Therapeutics (ALDX) in Q4 2024, closing a stake of 92,522 shares — an estimated $499K sold.

EAM Investors first reported a position in ALDX in Q3 2018 and held it in 8 quarters. The position peaked at $4.31M in Q3 2018. 119 funds tracked by Wall St. Rank hold ALDX as of Q4 2024.

EAM Investors reported no remaining Aldeyra Therapeutics position as of Q4 2024 after selling out during the quarter.
EAM Investors sold 92,522 Aldeyra Therapeutics shares in Q4 2024, an estimated $499K.
EAM Investors first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 8 quarters.
EAM Investors's Aldeyra Therapeutics position peaked at $4.31M in Q3 2018.
119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.